Inibsacain (Bupivacaine Hydrochloride, Epinephrine)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, stopping the generation and transmission of electrical impulses. This interruption prevents pain signals from reaching the brain. Epinephrine added to the formulation causes local blood‑vessel constriction, slowing systemic absorption and prolonging the anesthetic effect.

The dose of Inibsacain is determined by the prescribing clinician based on the specific procedure, patient weight, and maximum safe limits. Practitioners calculate the volume required to achieve adequate anesthesia while staying within recommended safety thresholds.

Safety data for bupivacaine with epinephrine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Inibsacain product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both Inibsacain (bupivacaine with epinephrine) and lidocaine are local anesthetics, but bupivacaine provides a longer duration of action, especially when combined with epinephrine. Lidocaine has a faster onset but a shorter overall effect, making bupivacaine preferable for lengthy dental or oral‑surgical procedures.

Inibsacain should be stored below 25 °C in its original container, protected from moisture and direct light. Maintaining a stable room‑temperature environment helps preserve the sterility and potency of the solution.

Inibsacain is administered by dental infiltration, where the sterile solution is injected directly into the tissues surrounding the target tooth or surgical site. The clinician follows aseptic technique and injects the calculated volume to achieve adequate numbness before the procedure begins.

Serious risks include cardiovascular toxicity such as arrhythmias or hypotension, central nervous system effects like seizures or loss of consciousness, severe allergic reactions (anaphylaxis), and persistent nerve injury leading to long‑term paresthesia. Immediate medical attention is required if any of these symptoms appear.

Patients with known hypersensitivity to bupivacaine, epinephrine, or any component of the formulation should avoid Inibsacain. It is also contraindicated in individuals with severe cardiac conduction disorders, uncontrolled hypertension, or those taking certain interacting medications without close medical supervision.